Reverba Unveils Updated Brand Identity as Reverba Global™, Reflecting the Company’s Expansion and Global Capabilities as a Leader in Healthcare Engagement

Seattle, WA – April 07, 2025 – Reverba, a leader in healthcare engagement, today announced its rebranding as Reverba Global in response to accelerated company growth and international scope. At the heart of this rebranding is expansion of its corporate vision to transform healthcare engagement for better outcomes through a wide range of bespoke, authentic,…

Reverba Global;

Seattle, WA – April 07, 2025 Reverba, a leader in healthcare engagement, today announced its rebranding as Reverba Global in response to accelerated company growth and international scope. At the heart of this rebranding is expansion of its corporate vision to transform healthcare engagement for better outcomes through a wide range of bespoke, authentic, scientifically rigorous and compliant communications channels and programs.

For nearly 25 years, Reverba (formerly Health Perspectives Group) has partnered with biopharmaceutical companies to foster meaningful connections between patients, caregivers, and healthcare professionals (HCPs) with expert patient recruitment and proprietary technology solutions. Through acquisitions, Reverba Global is strengthening its medical affairs and scientific engagement capabilities, supporting the company’s ability to deliver comprehensive patient engagement and scientific communications solutions touching all aspects of the biopharma product lifecycle – drug development, clinical trials, medical affairs, launch, commercialization and market maturity.

The transition to Reverba Global reflects a new chapter of growth and impact based on the company’s expanded mission to innovate and build connections worldwide, with more than 190 team members in the U.S., Canada and the U.K., serving more than 40 countries and more than 450 disease areas.

“Reverba Global embodies our team’s dedication to accessible and accurate medical information, empowering patients to manage their care and their health,” said Cheryl Lubbert, CEO of Reverba Global. “We know the biopharma marketplace knows no borders, and the patient experience is universal. We strive to be the premier health engagement partner for biopharmaceutical companies, building relationships with patients and HCPs, amplifying patient voices and fostering deeper engagement that drives transformation in healthcare.”

About Reverba Global

Reverba Global is a world-class tech-enabled health engagement company that provides solutions to empower the biopharmaceutical industry to forge deeper, more impactful connections with patients, families, healthcare providers and other key health stakeholders through innovative technology and compliant, patient-centric approaches from discovery through commercialization. Since 2002, Reverba Global has incorporated compliance throughout its technology platforms and healthcare engagement solutions, maintaining SOC 2 Type II certification for the highest level of security. Formed from the mergers of Health Advocacy Strategies, Patient Health Perspectives, and Health Perspectives Group, the company rebranded as Reverba in 2021, and with expansion beyond the U.S. through acquisitions including Six Degrees Worldwide Inc. rebranded as Reverba Global in 2025. Health Stories Project, a wholly owned subsidiary of Reverba Global, is a sharing community about personal health experiences, participation in clinical trials, and other activities.

For more information, visit reverba.com, follow us on LinkedIn or contact connect@reverba.com.

For media inquiries, please contact:

Kira Gordon
Email: kira@brightpointny.com
Phone: (646) 243-4920


The Latest

  • RWE Reality Check: Closing the Gap Between Data and Decision-Making in Medical Affairs
    RWE Reality Check: Closing the Gap Between Data and Decision-Making in Medical Affairs

    Medical Affairs teams have more real-world data and more advanced analytics than ever, but decision-making is not getting easier. This article explores why more RWE and AI are not translating…

  • Medical Affairs ROI: Turning Scientific Engagement Into Measurable Impact
    Medical Affairs ROI: Turning Scientific Engagement Into Measurable Impact

    Interactions led by Medical Affairs, including scientific exchange with HCPs and engagement with patients and advocacy groups, can influence clinical decisions and patient behavior, but their impact is not always…

  • Cheryl Lubbert, CEO of Reverba Global, Named 2026 HBA Luminary Award Honoree
    Cheryl Lubbert, CEO of Reverba Global, Named 2026 HBA Luminary Award Honoree

    Cheryl Lubbert, CEO of Reverba Global, has been named a 2026 HBA Luminary Award honoree by the Healthcare Businesswomen’s Association. The recognition reflects her leadership in advancing scientific engagement and…